Grown Rogue International (GRUSF) Interest & Investment Income (2024 - 2026)
Grown Rogue International's (GRUSF) quarterly Interest & Investment Income came in at $42187.0 in Q1 2026, up 17.39% year-on-year from $35937.0 in Q1 2025, and up 100.0% quarter-over-quarter from -$1218.4 billion in Q4 2025.
Grown Rogue International (GRUSF) Interest & Investment Income (2024 - 2026) Analysis & Trends
Grown Rogue International's Interest & Investment Income history runs 3 years deep, the most recent figure standing at $42187.0 for Q1 2026.
- On a quarterly basis, Interest & Investment Income rose 17.39% year-over-year to $42187.0 in Q1 2026; TTM through Mar 2026 was -$782.1 billion, a 198.97% decrease from a year earlier, with the FY2025 full-year figure at $703068.0, up 100.5% from the prior year.
- Interest & Investment Income climbed to $42187.0 in Q1 2026 per GRUSF's latest filing, from -$1218.4 billion in the prior quarter.
- Across five years, Interest & Investment Income topped out at $436.3 billion in Q3 2025 and bottomed at -$1218.4 billion in Q4 2025.
- The 3-year median for Interest & Investment Income is $99298.0 (2024), against an average of -$116.0 billion.
- Biggest YoY gain for Interest & Investment Income was 142.54% in 2025; the steepest drop was 155.76% in 2025.
- Year by year, Interest & Investment Income stood at -$476.4 billion in 2024, then plunged by 155.76% to -$1218.4 billion in 2025, then jumped by 100.0% to $42187.0 in 2026.
- Per Business Quant, the three latest GRUSF Interest & Investment Income figures stand at $42187.0 (Q1 2026), -$1218.4 billion (Q4 2025), and $436.3 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Grown Rogue International | 99.32 Mn | 85.61 Mn | 3.96 Mn | 42,187.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42,187.00 |
| Dec 31, 2025 | -1,218.45 Bn |
| Sep 30, 2025 | 436.32 Bn |
| Jun 30, 2025 | 393,669.00 |
| Mar 31, 2025 | 35,937.00 |
| Dec 31, 2024 | -476.39 Bn |
| Sep 30, 2024 | 214.79 Bn |
| Jun 30, 2024 | 162,312.00 |
| Mar 31, 2024 | 99,298.00 |